（原标题：揭秘涨停丨政策利好，跨境支付概念多股涨停） 今日A股市场收盘共93股涨停，剔除掉12只ST个股后，有81股涨停，26股封板未遂，整体封板率为 78.15%。 涨停战场：ST新潮超百万手买单封板 从收盘涨停板封单量来看，ST新潮封单量最高，有100.79万手；其次是保税科技、步步高、中油资本， 涨停板封单分别为59.15万手、56.5万手、49.69万手。 从连续涨停天数来看，安记食品6连板，天保基建5连板，保税科技、红墙股份4连板，天元股份、百大 集团、威尔药业3连板，ST新潮、跨境通、海联金汇等15股2连板，乐山电力7日6板、步步高4日3板 等。 以封单金额计算，21股封单资金超1亿元，中油资本、青岛金王、海联金汇封单资金居前，分别为3.93 亿元、3.42亿元、3.36亿元。 中油资本具有国际结算概念，公司此前在投资者问答平台上表示，中油资本所属金融企业昆仑银行的跨 境人民币业务在人民银行和相关监管机构统一指导和安排下进行，在人民币国际化进程中，积极推动跨 境人民币结算，在服务油气主业、保障国家能源安全方面做出应有贡献。 龙头点睛：跨境支付板块多股涨停 1.跨境支付 涨停个股：青岛金王、海联金汇 ...

Core Viewpoint - The competition in the weight loss drug market is intensifying, with Eli Lilly making significant strides to challenge Novo Nordisk's long-standing dominance, although both companies are expected to maintain leading positions in the market [2][4]. Group 1: Company Performance and Competition - Novo Nordisk has been facing increased competition from Eli Lilly, which has been innovating and investing to catch up, but has not yet surpassed Novo Nordisk [2]. - Eli Lilly's next-generation weight loss drug, Orforglipron, has shown promising results in Phase III clinical trials, with an average weight reduction of 7.9%, outperforming some early studies of Novo Nordisk's Ozempic [4]. - Eli Lilly's management emphasizes the advantages of oral drug commercialization, including easier scalability and cost advantages, which could enhance its long-term revenue and profit outlook [5]. Group 2: Market Dynamics and Investor Sentiment - Despite a general downward revision of revenue and profit expectations for Eli Lilly, analysts remain optimistic about its growth prospects, contrasting with the sentiment towards Novo Nordisk [7]. - Eli Lilly's ability to scale production in the U.S. is seen as more favorable compared to Novo Nordisk, although potential supply chain disruptions due to trade wars could impact its margins [7]. - The valuation of Eli Lilly is currently high, with an expected EBITDA multiple of 28.5, above its 10-year average of 22.1, indicating that the company must continue to diversify its product line to justify its growth metrics [9]. Group 3: Stock Performance and Investment Considerations - Investors are advised to consider the changing trend of Eli Lilly's stock, which has shown signs of losing momentum after peaking in 2024, with a critical support level at $700 [11]. - Analysts suggest waiting for a potential pullback after recent stock price increases to consider additional investments, while maintaining a bullish outlook based on the successful Phase III results of its weight loss drug [11].

Market Overview - A-shares opened steadily with the Shanghai Composite Index up 0.25%, Shenzhen Component Index up 0.7%, and the ChiNext Index increasing by 3% [1] - Hong Kong stocks performed well, with the Hang Seng Technology Index opening up over 3% [2] - FTSE China A50 Index futures rose by more than 4% [3] - Japanese and South Korean stock markets showed signs of rebound, with Japan's market performing relatively stronger [4][13] A-share Performance - The ChiNext Index opened with a strong performance, rising by 1.68% during the continuous bidding phase, while the Shanghai Composite Index turned positive [6] - Key sectors leading the gains included transportation equipment, semiconductors, securities, hotel and catering, oil, and coal [6] Sector Performance - Transportation Equipment: +1.88% [7] - Securities: +0.82% [7] - Hotel and Catering: +0.73% [7] - Notable concept stocks such as seed industry, weight loss drugs, and BC batteries also saw significant gains [8] Hong Kong Market Performance - The Hong Kong market opened higher, with the Hang Seng Index up 1.66% and the Hang Seng Technology Index up 3.31% [9] - Major constituents of the Hang Seng Technology Index, including JD.com, Tencent Music, and NetEase, showed strong performance [10] Central Bank and Regulatory Actions - Central Huijin Investment expressed confidence in the current A-share allocation value, indicating plans to increase investment in various market styles and ETFs [11] - The National Financial Regulatory Administration announced adjustments to insurance fund equity asset regulations, raising the upper limit for equity asset allocation and encouraging investment in strategic emerging industries [12] International Market Context - Japanese stocks, particularly in electronics and chips, showed strong rebound, with the Nikkei 225 Index rising over 5% at one point [14][15] - South Korean market's rebound was weaker, with the KOSPI Index showing a maximum increase of over 2% [17] - In the international commodities market, gold prices fell below $3,000 per ounce, declining over 1% [18]

Group 1 - The recombinant protein concept sector rose by 2.32%, ranking fifth among concept sectors, with 40 stocks increasing in value [1] - Notable gainers in the sector included Xilong Science, which hit the daily limit, and other companies like Maiwei Biotech, Hotgen Biotech, and Zexin Pharmaceutical, which rose by 11.05%, 8.16%, and 7.91% respectively [1] - The sector experienced a net inflow of 354 million yuan from main funds, with 23 stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top stocks by net inflow included Xilong Science with 282 million yuan, followed by Huabei Pharmaceutical, Borui Pharmaceutical, and Maiwei Biotech with net inflows of 29.71 million yuan, 27.06 million yuan, and 14.97 million yuan respectively [2][3] - Xilong Science led the sector with a net inflow rate of 30.58%, followed by Innotec and Kexing Pharmaceutical with rates of 13.12% and 11.83% respectively [3] - The overall performance of the recombinant protein sector reflects strong investor interest and capital flow, indicating potential growth opportunities within this industry [2][3]